| Name | Title | Contact Details |
|---|
Osceola Regional Medical Center is a Kissimmee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DPS Health is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Washington Health System provides an integrated healthcare system centered around patients and families. They have been dedicated to providing the highest quality care since 1897. With locations throughout Washington and Greene counties in Pennsylvania...
Healthcare industry veterans Joe Caruncho – whose success at the helm of Preferred Care Partners led to annual sales in excess of $750 million – and Orlando Lopez-Fernandez, Jr., MD, founded Genuine Health Group to usher in a new era of healthcare delivery focused on value instead of volume. Today, Genuine Health is building a model for managing care delivery that embodies traditional values, promises reliability, and embraces flexibility and technology. Through its accountable care organization, PremierMD ACO, the company aims to improve healthcare outcomes, achieve cost savings for the care of patients who receive traditional, fee-for-service Medicare benefits, and serve as a single point of contact to move doctors` Medicare members into value-based care. And, through its management service organization (MSO), the company aims to deliver financial upside for its participating physicians whose patients are enrolled in Medicare Advantage plans. For both traditional Medicare beneficiaries and those who choose managed care plans, Genuine Health and its providers are demonstrating the powerful effects of value-based care.
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.